Articles

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA
Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona, Spain
Maria Sklodowska–Curie National Research Institute of Oncology, Kraków, Poland
Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy
Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA
1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain
Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, United Kingdom
Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
Department of Medicine III, LMU University Hospital, Munich, Germany
Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand, France
Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg, Germany
Institute of Pathology, University of Würzburg, Würzburg, Germany
MorphoSys AG, Planegg, Germany
MorphoSys AG, Planegg, Germany
MorphoSys AG, Planegg, Germany
Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France
Haematologica Early view Jul 1, 2021 https://doi.org/10.3324/haematol.2020.275958